Table 1 Characteristics of naive subjects with and without presumed advanced fibrosis
Characteristics | Subjects with presumed fibrosis1 reinvestigated | Subjects with presumed fibrosis1 not reinvestigated | Subjects without presumed fibrosis |
|---|---|---|---|
Number of subjects | 105 | 104 | 7254 |
Age at serum, years (mean;95%CI) | 66.5 (64.7-68.2) | 63.6 (62.0-65.2) | 56.7 (56.5-56.9) |
Male (%; 95%CI) | 94 (0.90;0.82-0.95) | 95 (0.91;0.84-0.96) | 3924 (0.54;0.53-0.55) |
Tobacco consumption | 63/105 (0.60;0.50-0.69) | 54/104 (0.52;0.42-0.62) | 3245/7247 (0.45;0.44-0.46) |
No physical exercise | 65/105 (0.62;0.52-0.71) | 60/104 (0.58;0.48-0.67) | 4685/7247 (0.65;0.64-0.66) |
Retired | 70 (0.67;0.57-0.76) | 58 (0.56;0.46-0.66) | 2224 (0.31;0.30-0.32) |
Fatty liver risk factor (Alcohol or metabolic) | 98 (0.93;0.87-0.97) | 86 (0.83;0.74-0.89) | 4698 (0.65;0.64-0.66) |
Mean daily self-reported alcohol consumption | 11.6 (8.2-15.0) | 15.3 (11.4-19.3) | 9.9 (9.6-10.3) |
Self-reported alcohol consumption at risk2 | 24/105 (0.23;0.15-0.32) | 28/104 (0.27;0.19-0.37) | 1634/7247 (0.23;0.22-0.24) |
CDT assessed | 72/105 (0.69;0.59-0.77) | 2/104 (0.02;0.00-0.07) | 1023/7254 (0.14;0.13-0.15) |
Carbohydrate Deficient Transferin | 1.92 (1.76-2.07) | 1.49 (1.24-1.74) | 1.51 (1.48-1.54) |
Elevated Carbohydrate Deficient Transferin (>1.6%)3 | 45/72 (0.63;0.50-0.74) | NP | 303/1023 (0.30;0.27-0.33) |
Alcohol at risk (either reported consumption or CDT)3 | 54/72 (0.75;0.63-0.85) | NP | 426/1023 (42%) |
BMI >= 27.0 | 57 (0.54;0.44-0.64) | 49 (0.47;0.37-0.57) | 2319/7245 (0.32;0.31-0.33) |
Metabolic factor of ATP-III classification (at least one) | 83 (0.79;0.70-0.86) | 80 (0.77;0.68-0.85) | 3827 (0.53;0.52-0.54) |
Glucose >= 6.1 mmol/L or diabetes treatment | 34/103 (0.33;0.24-0.43) | 42/104 (0.40;0.31-0.51) | 1069/7253 (0.15;0.14-0.16) |
Central obesity waist >102 male >88 female | 30/105 (0.29;0.20-0.38) | 28/104 (0.27;0.19-0.37) | 1162/7245 (0.16;0.15-0.17) |
Triglycerides >= 1.7 mmol/L or fibrate treatment | 43/101 (0.41;0.32-0.51) | 37/104 (0.36;0.26-0.46) | 1707/7199 (0.24;0.23-0.25) |
Hypertension or treatment | 44/105 (0.42;0.32-0.52) | 41/104 (0.39;0.30-0.50) | 1885/7240 (0.26;0.25-0.27) |
HDL-cholesterol <1.03 mmol/L male <1.29 mmol/L female missing 2564 | 16/72 (0.22;0.13-0.34) | 12/68 (0.18; 0.10-0.29) | 328/4764 (0.07;0.06-0.08) |
Steatosis predicted by SteatoTest | |||
No | 23/101 (0.23;0.15-0.32) | 31/104 (0.30;0.21-0.40) | 4174/7190 (0.58;0.57-0.59) |
Minimal (1-5%) | 37/101 (0.37;0.27-0.47) | 33/104 (0.32;0.23-0.42) | 1617/7190 (0.23;0.22-0.24) |
Moderate (6-33) | 19/101 (0.19;0.12-0.28) | 15/104 (0.14;0.08-0.23) | 706/7190 (0.10;0.09-0.11) |
Marked-Severe (34-100%) | 22/101 (0.22;0.14-0.31) | 25/104 (0.24;0.16-0.33) | 693/7190 (0.10;0.09-0.10) |
Steatohepatitis predicted by NASHTest | 7/101 (0.07;0.03-0.13) | 11/104 (0.11;0.05-0.18) | 62/7190 (0.009;0.007-0.011) |
Risk HCV (Transfusion, tattoo, piercing, heroin, cocaine) | 1 (0.010;0.000-0.052) | 1 (0.010;0.000-0.052) | 163 (0.023;0.019-0.026) |
HCV antibody assessed | 105/105 (1.00;0.97-1.00) | 52/104 (0.50;0.40-0.60) | 3473/7254 (0.48;0.47;0.49) |
HCV antibody positive | 5/105 (0.05;0.02-0.11) | 1/52 (0.02;0.00-0.10) | 26/3473 (0.008;0.005-0.011) |
HIV antibody positive | 1/63 (0.02;0.00-0.09) | 0/6 (0.00;0.00-0.46) | 1/944 (0.001;0.000-0.006) |
HBsAg assessed | 105/105 (1.00;0.97-1.00) | 8/104 (0.08;0.03-015) | 604/7254 (0.08;0.077-0.090) |
HBsAg antigen positive | 2/105 (0.02;0.00-0.07) | 0/104 (0.00;0.00-0.04) | 5/604 (0.008; 0.003-0.019) |
Liver stiffness measurement assessed | 93/105 (0.86;0.81-0.94) | 0/104 (0.00;0.00-0.04) | 865/7254 (0.12;0.11-0.13) |
LSM kPa | 10.1 (8.3-12.0) | NP | 5.0 (4.8-5.1) |
Markers (normal range) | |||
AST IU/L (17-27 female; 20-32 male) | 34 (31-37) | 40 (34-46) | 24 (24-24) |
ALT IU/L (11-26 female; 16-35 male) | 43 (37-50) | 46 (38-54) | 27 (26-27) |
Total bilirubin mol/L (1-21) | 16 (14-17) | 16 (14-17) | 12 (12-12) |
GGT U/L (7-32 female; 11-49 male) | 72 (56-87) | 111 (75-146) | 27 (26-27) |
Alpha 2 macroglobulin g/L (female 1·6-4·0; male 1·4-3·3) | 2.4 (2.3-2.5) | 2.4 (2.3-2.5) | 1.5 (1.5-1.5) |
Apo A1 g/L (1·2-1·7) | 1.5 (1.4-1.5) | 1.5 (1.4-1.5) | 1.7 (1.7-1.7) |
Haptoglobin g/L (0·35-2·00) | 0.9 (0.8-1.0) | 0.8 (0.7-0.9) | 1.2 (1.1-1.2) |
Fasting Glucose (mmol/L) | 6.1 (5.8-6.4) | 6.4 (6.0-6.8) | 5.5 (5.5-5.5) |
Cholesterol (mmol/L) | 5.3 (5.1-5.5) | 5.4 (5.1-5.6) | 5.8 (5.7-5.8) |
Triglycerides (mmol/L) | 1.7 (1.3-2.0) | 1.8 (1.4-2.2) | 1.3 (1.3-1.3) |
HDL-cholesterol (data in 72/68/4764 subjects) | 0.49 (0.46-0.51) | 0.51 (0.47-0.54) | 0.63 (0.62-0.63) |